Rakovina Therapeutics Inc. announced the Company's poster presentation at the AACR Annual Meeting. Rakovina Therapeutics presentation entitled Evaluation of a Novel Class of Bifunctional DNA Alkylating PARP Inhibitors was
delivered during the Combination Therapeutics session on April 11, 2022 and highlights pre-clinical research related to its novel kt-4000 series. The data presented suggested promising activity for bi-functional kt-4000 series compounds. Rakovina Therapeutics poster presentation will be made available on the company's website following the conclusion of the AACR Annual Meeting. kt-4000 represents a novel class of small molecule drug candidates that combine potent inhibition of polyADP-ribose polymerase (PARP) with DNA alkylating functionality in a single molecule. Select kt-4000 lead candidates are being advanced to evaluate pharmacokinetics, preliminary safety profile and anti-tumor activity in vivo.